Sensitivity (95% CI) | Specificity (95% CI) | Positive Likelihood Ratio (95% CI) | Negative Likelihood Ratio (95% CI) | AUROC (95% CI) | |
---|---|---|---|---|---|
Single frailty tests | |||||
CFS > 4 | 50.0 (18.7–81.3) | 94.2 (85.8–98.4) | 8.62 (2.77–26.84) | 0.53 (0.28–0.99) | 0.76 (0.66–0.85) |
GST5m ≥ 6 s | 81.5 (61.9–93.7) | 63.5 (49.0–76.4) | 2.23 (1.49–3.33) | 0.29 (0.13–0.66) | 0.73 (0.62–0.83) |
Muscle thickness (MTRFM) ≤ 1.40 cm | 62.8 (46.7–77.0) | 61.1 (43.5–76.9) | 1.61 (1.01–2.58) | 0.61 (0.38–0.97) | 0.63 (0.51–0.73) |
Muscle cross-sectional area (CSARFM) ≤ 3.015 cm2 | 45.5 (16.7–76.6) | 94.1 (85.6–98.4) | 7.73 (2.45–24.4) | 0.58 (0.34–1.00) | 0.64 (0.52–0.74) |
Muscle echogenicity (EchoRFM) > 45.85 au | 53.6 (33.9–72.5) | 78.4 (64.7–88.7) | 2.48 (1.33–4.65) | 0.59 (0.39–0.90) | 0.66 (0.55–0.77) |
Add-on test | |||||
GST5m + CSARFM | 71.4 (29.0–96.3) | 94.4 (86.4–98.5) | 12.86 (4.45–37.16) | 0.30 (0.09–0.98) | 0.90 (0.81–0.95) |